ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

BNR Burning Rock Biotech Ltd

0.35
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Burning Rock Biotech Ltd LSE:BNR London Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 0.35 0 01:00:00

Blenheim Natural Resources PLC Result of General Meeting (7221D)

28/04/2017 1:38pm

UK Regulatory


Burning Rock Biotech (LSE:BNR)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Burning Rock Biotech Charts.

TIDMBNR

RNS Number : 7221D

Blenheim Natural Resources PLC

28 April 2017

28 April 2017

BLENHEIM NATURAL RESOURCES PLC

("Blenheim" or the "Company")

Result of General Meeting

Blenheim is pleased to announce that at the Company's General Meeting held earlier today, both resolutions were duly passed.

As a result, shareholders have granted the directors the authority to allot and issue up to 75,000,000 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares"), (the "Consideration Shares"), as partial consideration for the conditional acquisition of a 30 per cent interest in Nashwan Holdings Ltd ("Nashwan"), as announced by the Company on 30 March 2017. The remaining consideration for the investment in Nashwan is GBP200,000 in cash (the "Cash Consideration"). Completion of the Company's investment in Nashwan was conditional on shareholders granting the directors the authority to allot and issue the Consideration Shares and will now take place within 5 business days.

Pursuant to the terms of the acquisition, the issue of the Consideration Shares and the payment of the Cash Consideration to Mr Harry Sutherland remains conditional on Nashwan successfully being granted with exploration licences over both its Menianbala and Djidje projects within 90 days of the date of completion, or by such other date agreed between the parties. Blenheim will make further announcements in this respect in due course.

Shareholders have also granted the directors the authority to allot and issue Ordinary Shares on a non-pre-emptive basis up to an aggregate nominal amount of GBP398,577. Accordingly, the Company now has the requisite authority to complete the conditional placing of 222,222,222 Ordinary Shares to raise GBP1 million before expenses, and to issue 11,111,111 warrants over Ordinary Shares to Cornhill Capital Limited, the Company's broker (announced on 27 April 2017).

Application has been made for 222,222,222 new Ordinary Shares, which rank pari passu with the Company's existing issued Ordinary Shares, to be admitted to trading on the AIM Market of the London Stock Exchange ("AIM"). Dealings on AIM are expected to commence at 8:00 a.m. on or around 3 May 2017 ("Admission").

Further to the announcement of 27 April 2017, and pursuant to the authorities granted by shareholders at the Company's general meeting of shareholders held on 7 February 2017, GBP1 of the proceeds of the placing, having been raised for this specific purpose, shall be used by the Company to redeem in total the 23,790 deferred shares of GBP49 each in the capital of the Company in issue (the "Deferred Shares"). The Deferred Shares carry no voting rights and have effectively no economic value. The redemption of the Deferred Shares will be completed as soon as reasonably practicable following Admission.

Total Voting Rights

Following Admission, the issued share capital of the Company will comprise 620,798,836 Ordinary Shares with voting rights attached (one vote per share). The Company does not hold any shares in treasury. This figure of 620,798,836 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Ends

For further information please contact:

 
Chris Ells                                  Blenheim Natural Resources Plc         +44 (0) 1622 844601 
 
Colin Aaronson/Jamie Barklem/ Daniel Bush   Grant Thornton UK LLP                  +44 (0) 20 7383 5100 
 
Nick Emerson                                SI Capital Ltd                         +44 (0)1483 413500 
Lucy Williams / Duncan Vasey                Peterhouse Corporate Finance Limited   +44 (0) 20 7469 0932 
Colin Rowbury                               Cornhill Capital Limited               +44 (0) 20 7710 9610 
 

The information contained within this announcement is considered to be inside information, for the purposes of Article 7 of EU Regulation 596/2014, prior to its release.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGLVLFLDZFXBBZ

(END) Dow Jones Newswires

April 28, 2017 08:38 ET (12:38 GMT)

1 Year Burning Rock Biotech Chart

1 Year Burning Rock Biotech Chart

1 Month Burning Rock Biotech Chart

1 Month Burning Rock Biotech Chart

Your Recent History

Delayed Upgrade Clock